JP2012501337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501337A5 JP2012501337A5 JP2011525178A JP2011525178A JP2012501337A5 JP 2012501337 A5 JP2012501337 A5 JP 2012501337A5 JP 2011525178 A JP2011525178 A JP 2011525178A JP 2011525178 A JP2011525178 A JP 2011525178A JP 2012501337 A5 JP2012501337 A5 JP 2012501337A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- phenyl
- pharmaceutically acceptable
- acceptable salt
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 6
- 150000001204 N-oxides Chemical class 0.000 claims 5
- -1 C 1 -C 6 alkylene Alkyne Chemical class 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical group C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims 3
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 claims 3
- 239000005964 Acibenzolar-S-methyl Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical group C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical group C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 2
- 239000012964 benzotriazole Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- AGTXZUSQQMGXGX-UHFFFAOYSA-N 1,4-dihydropyrrolo[3,2-b]pyrrole Chemical compound N1C=CC2=C1C=CN2 AGTXZUSQQMGXGX-UHFFFAOYSA-N 0.000 claims 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims 1
- LJMZRBZETLXDSO-UHFFFAOYSA-N 1h-thieno[3,2-c]pyrazole Chemical compound N1N=CC2=C1C=CS2 LJMZRBZETLXDSO-UHFFFAOYSA-N 0.000 claims 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical group C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZTYYDUBWJTUMHW-UHFFFAOYSA-N furo[3,2-b]furan Chemical compound O1C=CC2=C1C=CO2 ZTYYDUBWJTUMHW-UHFFFAOYSA-N 0.000 claims 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical group C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Chemical group CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Chemical group C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical group C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003536 tetrazoles Chemical group 0.000 claims 1
- ONCNIMLKGZSAJT-UHFFFAOYSA-N thieno[3,2-b]furan Chemical compound S1C=CC2=C1C=CO2 ONCNIMLKGZSAJT-UHFFFAOYSA-N 0.000 claims 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical group C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 claims 1
- 239000002175 thienopyridine Chemical group 0.000 claims 1
- 229940125670 thienopyridine Drugs 0.000 claims 1
- 229930192474 thiophene Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical group 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9236408P | 2008-08-27 | 2008-08-27 | |
| US61/092,364 | 2008-08-27 | ||
| US14284609P | 2009-01-06 | 2009-01-06 | |
| US61/142,846 | 2009-01-06 | ||
| US14373909P | 2009-01-09 | 2009-01-09 | |
| US61/143,739 | 2009-01-09 | ||
| US15727409P | 2009-03-04 | 2009-03-04 | |
| US61/157,274 | 2009-03-04 | ||
| US15870209P | 2009-03-09 | 2009-03-09 | |
| US15871009P | 2009-03-09 | 2009-03-09 | |
| US61/158,710 | 2009-03-09 | ||
| US61/158,702 | 2009-03-09 | ||
| PCT/US2009/055090 WO2010027875A2 (en) | 2008-08-27 | 2009-08-26 | Compounds that modulate intracellular calcium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501337A JP2012501337A (ja) | 2012-01-19 |
| JP2012501337A5 true JP2012501337A5 (enExample) | 2012-10-04 |
| JP5782377B2 JP5782377B2 (ja) | 2015-09-24 |
Family
ID=41722281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525178A Expired - Fee Related JP5782377B2 (ja) | 2008-08-27 | 2009-08-26 | 細胞内カルシウムを調節する化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7981925B2 (enExample) |
| EP (1) | EP2321303B1 (enExample) |
| JP (1) | JP5782377B2 (enExample) |
| KR (1) | KR101724161B1 (enExample) |
| CN (1) | CN102256969A (enExample) |
| AU (1) | AU2009288245B2 (enExample) |
| BR (1) | BRPI0917719A2 (enExample) |
| CA (1) | CA2734500A1 (enExample) |
| IL (1) | IL211391B (enExample) |
| MX (1) | MX2011002149A (enExample) |
| MY (1) | MY157445A (enExample) |
| RU (1) | RU2472791C2 (enExample) |
| TW (1) | TWI392673B (enExample) |
| WO (2) | WO2010027875A2 (enExample) |
| ZA (1) | ZA201101335B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR101724161B1 (ko) * | 2008-08-27 | 2017-04-06 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
| US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8618307B2 (en) * | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| IN2012DN03312A (enExample) * | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| TWI504404B (zh) * | 2010-07-22 | 2015-10-21 | Univ Kaohsiung Medical | 用於抑制結腸直腸癌細胞及子宮上皮癌細胞生長轉移之醫藥組合物 |
| WO2012027710A2 (en) | 2010-08-27 | 2012-03-01 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US20120071516A1 (en) * | 2010-09-22 | 2012-03-22 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| NZ609572A (en) | 2010-10-30 | 2015-05-29 | Lupin Ltd | Oxazoline and isoxazoline derivatives as crac modulators |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| US9409898B2 (en) | 2012-05-02 | 2016-08-09 | Lupin Limited | Substituted pyrazole compounds as CRAC modulators |
| CN104395326B (zh) * | 2012-08-20 | 2017-04-05 | 玛耐科股份有限公司 | 二取代硼酸衍生物的制造方法和新型二取代硼酸衍生物 |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| WO2014207648A1 (en) | 2013-06-24 | 2014-12-31 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| BR112016030690B1 (pt) | 2014-06-27 | 2023-11-14 | Nogra Pharma Limited | Compostos moduladores do receptor de arila, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos |
| EP3189048B1 (en) | 2014-09-03 | 2021-03-17 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| EP3189041B1 (en) | 2014-09-03 | 2021-04-28 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| PT3203840T (pt) | 2014-10-06 | 2020-10-27 | Vertex Pharma | Moduladores do regulador da condutância transmembranar da fibrose quística |
| EP3261641B1 (en) | 2015-02-27 | 2023-07-12 | Calcimedica, Inc. | Pancreatitis treatment |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| EP3577103A1 (en) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Anti-fibrotic compounds |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| TWI719349B (zh) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Ｃｆｔｒ調節劑之結晶形式及組合物 |
| MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7399110B2 (ja) * | 2018-02-08 | 2023-12-15 | ウエヌイグレックオ・ファーマ | 非縮合チオフェン誘導体及びそれらの使用 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3849552A1 (en) | 2018-09-14 | 2021-07-21 | Rhizen Pharmaceuticals AG | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| US20240156778A1 (en) * | 2019-10-17 | 2024-05-16 | Enyo Pharma | Thiophene derivatives for use in treating portal inflammation and fibrosis |
| EP4192448A1 (en) * | 2020-08-05 | 2023-06-14 | ENYO Pharma | Thiophen compounds for use in the treatment of renal fibrosis |
| PE20250155A1 (es) | 2021-06-14 | 2025-01-22 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer |
| CN114436945B (zh) * | 2021-12-30 | 2023-12-22 | 山东师范大学 | 一种苯磺酰胺类化合物、制备方法及应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| GB1419074A (en) | 1972-06-09 | 1975-12-24 | Ici Ltd | Process for manufacturing substituted thiophene compounds |
| US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
| US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
| US4151273A (en) | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| DD201306A1 (de) | 1981-12-10 | 1983-07-13 | Juergen Liebscher | Verfahren zur herstellung von 5-acyl-3-aryl-2-dialkylaminothiophenen |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| DD216237A1 (de) | 1983-06-23 | 1984-12-05 | Univ Halle Wittenberg | Verfahren zur herstellung von substituierten 4-phenyl-thiophenen |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| DD235873A1 (de) | 1984-09-11 | 1986-05-21 | Univ Leipzig | Verfahren zur herstellung von substituierten thieno/2,3-d/1,3-thiazin-4-onen mit aminofunktionen in 2-stellung |
| DD240890A1 (de) | 1985-04-26 | 1986-11-19 | Univ Halle Wittenberg | Verfahren zur herstellung von n-(thien-2-yl)-n'-(alkoxycarbonylaryl-bzw.-alkyl)-thioharnstoffen |
| DE3529247A1 (de) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| CA1284642C (en) | 1986-03-31 | 1991-06-04 | Hikozo Iwakura | Prostacyclin (pgi ) analogues |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| EP0665010B1 (en) | 1992-10-16 | 2002-09-11 | Nippon Shinyaku Company, Limited | Method of manufacturing wax matrices |
| CA2148616C (en) | 1992-11-23 | 1998-02-03 | Laurence E. Burgess | Regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| CA2152792C (en) | 1993-01-15 | 2000-02-15 | Stephen R. Bertenshaw | Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
| US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
| US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
| US6020343A (en) | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| BR9708574A (pt) | 1996-04-12 | 1999-08-03 | Searle & Co | Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2 |
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| DE19642451A1 (de) * | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6037340A (en) | 1997-05-28 | 2000-03-14 | Cadus Pharmaceutical Corporation | Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1143013A1 (en) | 2000-04-03 | 2001-10-10 | Warner-Lambert Company | Methods and compositions for screening Icrac modulators |
| US6861419B2 (en) * | 2000-04-18 | 2005-03-01 | Cytovia, Inc. | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2002030976A1 (en) | 2000-10-11 | 2002-04-18 | The University Of Melbourne | Cell control nucleic acids and proteins |
| DE10061876A1 (de) | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| PL395097A1 (pl) * | 2001-06-11 | 2011-10-10 | Vertex Pharmaceuticals (Canada) Incorporated | Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu |
| US6599310B2 (en) | 2001-06-29 | 2003-07-29 | Quill Medical, Inc. | Suture method |
| NZ530782A (en) * | 2001-08-06 | 2005-11-25 | Pharmacia Italia S | Aminoisoxazole derivatives active as kinase inhibitors |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US6919359B2 (en) | 2001-11-08 | 2005-07-19 | Pfizer Inc | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| AR040123A1 (es) * | 2002-05-31 | 2005-03-16 | Upjohn Co | Compuestos tiofeno, antihelminticos e insecticidas |
| EP1532128A1 (en) | 2002-07-01 | 2005-05-25 | Pharmacia & Upjohn Company LLC | Inhibitors of hcv ns5b polymerase |
| US7410945B2 (en) * | 2002-10-16 | 2008-08-12 | The University Of Queensland | Treatment of inflammatory bowel disease |
| CA2504320A1 (en) * | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2004078995A2 (en) | 2003-03-04 | 2004-09-16 | Neurogenetics, Inc. | Methods of modulating and of identifying agents that modulate intracellular calcium |
| ATE537825T1 (de) | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| AU2003902851A0 (en) | 2003-06-06 | 2003-06-26 | Australian Ballet School | Ballet shoe insert |
| BRPI0412805A (pt) | 2003-07-23 | 2006-09-26 | Synta Pharmaceuticals Corp | método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio |
| JP4054741B2 (ja) * | 2003-09-26 | 2008-03-05 | 日本圧着端子製造株式会社 | 低背型ｆｐｃ用ｚｉｆコネクタ |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| WO2006093518A2 (en) * | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
| WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
| WO2006012642A2 (en) * | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| KR20070107022A (ko) | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| KR101436161B1 (ko) | 2005-01-25 | 2014-09-01 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| US8802721B2 (en) | 2005-01-25 | 2014-08-12 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| CN101142198B (zh) | 2005-02-17 | 2012-10-31 | 辛塔制药公司 | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 |
| US7563813B2 (en) * | 2005-05-13 | 2009-07-21 | Wyeth | Iminothiazolidinone derivatives as SFRP-1 antagonists |
| GB0516379D0 (en) | 2005-08-09 | 2005-09-14 | Glaxo Group Ltd | Compounds |
| EP1754483A1 (en) * | 2005-08-18 | 2007-02-21 | Merck Sante | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| CA2636417C (en) | 2006-01-05 | 2020-08-25 | Immune Disease Institute, Inc. | Regulators of nfat |
| WO2007083689A1 (ja) * | 2006-01-19 | 2007-07-26 | Renascience Co., Ltd. | プラスミノーゲンアクチベーターインヒビター－１阻害剤 |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| AU2007208240B2 (en) | 2006-01-25 | 2013-04-11 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| US8741960B2 (en) | 2006-01-25 | 2014-06-03 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| TWI417096B (zh) | 2006-01-25 | 2013-12-01 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之苯基及吡啶基化合物 |
| WO2007089904A2 (en) | 2006-01-31 | 2007-08-09 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| TW200812587A (en) | 2006-03-20 | 2008-03-16 | Synta Pharmaceuticals Corp | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| EP2004626A4 (en) | 2006-03-23 | 2010-10-27 | Synta Pharmaceuticals Corp | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS |
| EP2086326B1 (en) | 2006-11-13 | 2014-01-08 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| EP2121621B1 (en) * | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| WO2008122038A1 (en) | 2007-04-02 | 2008-10-09 | President And Fellows Of Harvard College | Regulating autophagy |
| CA2699157A1 (en) * | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| DE102007057905A1 (de) | 2007-11-29 | 2009-06-10 | Microtac Systems Ag | Haftverschlussteil und Verfahren zur Herstellung eines Haftverschlussteils |
| WO2009076454A2 (en) | 2007-12-12 | 2009-06-18 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR101724161B1 (ko) * | 2008-08-27 | 2017-04-06 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
| JP4879240B2 (ja) | 2008-09-16 | 2012-02-22 | 株式会社リコー | 発振回路、ｄｃ−ｄｃコンバータ及び半導体装置 |
| US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
-
2009
- 2009-08-26 KR KR1020117006529A patent/KR101724161B1/ko not_active Expired - Fee Related
- 2009-08-26 MX MX2011002149A patent/MX2011002149A/es not_active Application Discontinuation
- 2009-08-26 AU AU2009288245A patent/AU2009288245B2/en not_active Ceased
- 2009-08-26 CN CN2009801437215A patent/CN102256969A/zh active Pending
- 2009-08-26 MY MYPI2011000865A patent/MY157445A/en unknown
- 2009-08-26 US US12/548,186 patent/US7981925B2/en not_active Expired - Fee Related
- 2009-08-26 WO PCT/US2009/055090 patent/WO2010027875A2/en not_active Ceased
- 2009-08-26 RU RU2011108969/04A patent/RU2472791C2/ru not_active IP Right Cessation
- 2009-08-26 EP EP09812055.3A patent/EP2321303B1/en active Active
- 2009-08-26 BR BRPI0917719-1A patent/BRPI0917719A2/pt not_active IP Right Cessation
- 2009-08-26 US US12/548,189 patent/US7906553B2/en not_active Expired - Fee Related
- 2009-08-26 JP JP2011525178A patent/JP5782377B2/ja not_active Expired - Fee Related
- 2009-08-26 CA CA2734500A patent/CA2734500A1/en not_active Abandoned
- 2009-08-26 TW TW098128758A patent/TWI392673B/zh not_active IP Right Cessation
- 2009-08-27 WO PCT/US2009/055247 patent/WO2010025295A2/en not_active Ceased
-
2011
- 2011-01-14 US US13/006,701 patent/US8394848B2/en not_active Expired - Fee Related
- 2011-02-18 ZA ZA2011/01335A patent/ZA201101335B/en unknown
- 2011-02-24 IL IL211391A patent/IL211391B/en active IP Right Grant
- 2011-03-17 US US13/050,356 patent/US8372991B2/en not_active Expired - Fee Related
- 2011-03-17 US US13/050,724 patent/US8383670B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 US US13/733,795 patent/US20130245025A1/en not_active Abandoned
- 2013-01-04 US US13/734,087 patent/US20130231344A1/en not_active Abandoned